Morgan Stanley lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $52 from $55 and keeps an Equal Weight rating on the shares. The firm is slightly above consensus on Wainua Q1 royalty revenue estimates, the analyst tells investors in a preview heading into earnings for commercial small-to-mid cap biotechnology companies the analyst covers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Promising Growth with New Product Launches and Strong Pipeline
- Reddit initiated, Roku upgraded: Wall Street’s top analyst calls
- Ionis Pharmaceuticals: Poised for Growth with Promising RNA-Targeted Therapeutics and Upcoming Drug Launches
- Ionis Pharmaceuticals initiated with a Buy at H.C. Wainwright
- Ionis Pharmaceuticals management to meet with Oppenheimer